Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Non-system-forming list

Monday, February 9, 2015

On the 8 of February 2015, the Ministry of Economic Development of Russia published “The list of system-forming organizations”, who could get state support in times of crisis. Out of 199 companies included to the list only 7 are related to the pharmaceutical market. There are just 5 production companies: Open Joint Stock Company “Biosynthesis”, Federal State Unitary “Enterprise”, NPO “Microgen”, OJSC “Synthesis”, OJSC “Pharmstandart” and Closed Joint Stock Company “Binnopharm”. Overall annual volume of medical products output of these companies is 23,8% of the Russia total. With that, all above mentioned companies, excluding Binnopharm, are in top-10 by production volume.

Only two vaccine production companies will get the governmental support: NPO “Microgen” and “Binnopharm”. It is remarkable, that other major manufacturers, such as “Petrovax”, “Poliomyelitis and Virus Encephalitis Institute, named after M.P. Chumakov”, “St. Petersburg’s Vaccine and Serum Scientific Research Institute” could not count on the governmental support.

Only 3 pharmaceutical companies in the list produce pharmaceutical substances (OJSC “Biosynthesis”, OJSC “Synthesis”, OJSC “Pharmstandart”). However, in contrast to the finished medical products manufacturers, these companies take not more than 0,4% of the whole pharmaceutical substances volume, produced in Russia.

Among retail companies, only two can count on state support: OJSC “Aptechnaya set 36.6” (most likely the successor company is ment, “A.V.E. Group” chain) and OJSC “Protek” (“Rigla” pharmacy chain). Their summary market share is not more than 6%.

Thus, the governmental support in the pharmaceutical market is directed primarily to finished medical products manufacturers. At the same time it should be noted, that a place in the list still does not guarantee to a company any preferences.